Arrowhead, Amgen license and collaboration agreement closed

American Pharmacy News Reports | Nov 23, 2016
The agreement failed because of the early termination waiting period.
The agreement failed because of the early termination waiting period. | File image
Arrowhead Pharmaceuticals has closed the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA program.
The agreement fell through because of the early termination of the waiting period according to the Hart-Scott Rodino Antitrust Improvements Act of 1976.
More News

Brian Hanna, Executive Director of the Cannabis Regulatory Agency

State Issues Cannabis Regulatory Agency seeks new members for diversity, equity, and inclusion workgroup May 26, 2026

Sally Pipes, President & CEO of Pacific Research Institute

Innovation Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B' May 25, 2026

B. Douglas Hoey CEO

State Issues Tennessee enacts law banning pharmacy benefit managers from owning pharmacies May 22, 2026

Anne McDonald Pritchett, PhD, founder of Pritchett Policy Associates

Industry Pritchett Policy Associates founder Pritchett on biosimilar access: 'PBMs are the problem not patents' May 22, 2026

Ryan Long, Director of Congressional Relations & Senior Research Fellow at Paragon Health Institute

Federal Issues Paragon Health Institute senior fellow calls for 340B reform: Primary recipients of 340B are ‘wealthier larger hospital systems’ May 22, 2026

West Cuthbert, Senior Fellow, American Resolve Action

Federal Issues American Resolve Action Senior Fellow on 340B reform: Oversight 'could prevent billions of dollars in annual waste, fraud, and abuse' May 22, 2026

Trending

Sally Pipes, President & CEO of Pacific Research Institute

Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B'

B. Douglas Hoey CEO

Tennessee enacts law banning pharmacy benefit managers from owning pharmacies

Ted Okon, MBA, Executive Director, Community Oncology Alliance

Community Oncology Alliance Executive Director Okon on 340B: ‘Expanding participation in a flawed program isn’t reform’

Brian Blase, Ph.D., President of Paragon Health Institute

Paragon Health Institute links ACA and HRSA to 340B program growth, calls for reforms

West Cuthbert, Senior Fellow, American Resolve Action

American Resolve Action Senior Fellow on 340B reform: Oversight 'could prevent billions of dollars in annual waste, fraud, and abuse'